Group 1: Financial Performance - Merck expects sales for 2026 to be between $65.5 billion and $67 billion, with adjusted earnings per share projected at $5.00 to $5.15, which is below Wall Street expectations due to one-time costs from the acquisition of Cidara Therapeutics [2] Group 2: Company Status - Keytruda's key patent is expected to gradually expire starting in 2028, with its growth showing signs of slowing down, as evidenced by 2025 sales of $31.7 billion, reflecting a 7% year-over-year increase [3] - Merck is in talks to acquire biotechnology company Revolution Medicines for a potential price of $28 billion to $32 billion, aiming to enhance its oncology pipeline with the experimental drug Daraxonrasib [4] - Sales of the HPV vaccine Gardasil declined by 39% year-over-year to $5.233 billion in 2025, impacted by decreased demand in China and updated vaccination guidelines in the U.S., necessitating ongoing monitoring of its recovery [6] Group 3: Product Development Progress - The pulmonary arterial hypertension drug Winrevair (sotatercept) achieved sales of $1.443 billion in 2025 and is expected to gain FDA approval for new indications in 2026, positioning it as a key product [5] - Oral PCSK9 inhibitor Enlicitide and other cardiovascular products are in late-stage development and may represent new growth opportunities [5]

Core Insights - Merck (MRK.US) is actively pursuing acquisitions, product innovation, and new drug pipelines, which may significantly impact its future strategy and performance [1] Recent Events - Merck is in talks to acquire cancer drug developer Revolution Medicines for an estimated $28 billion to $32 billion, which would introduce the experimental drug Daraxonrasib targeting RAS gene mutation cancers, marking one of the largest deals in the pharmaceutical industry since Pfizer's acquisition of Seagen at the end of 2023 [2] - The company has also completed the acquisition of Cidara Therapeutics to strengthen its product pipeline [2] Business Progress - The subcutaneous formulation of Keytruda (Qlex) has been submitted for approval in the U.S., EU, and China, addressing challenges from the intravenous version's key patent expiration in 2028. Wolfe Research estimates that by 2029, approximately 41% of Keytruda's intravenous revenue may transition to the subcutaneous version [3] - New indications for Keytruda, including combination therapy with Moderna's mRNA vaccine and perioperative treatment for bladder cancer, are in progress [3] Performance Overview - The pulmonary arterial hypertension drug Winrevair (sotatercept) is projected to achieve sales of $1.443 billion by 2025 and is expected to receive FDA approval for new indications in 2026 [4] - The oral PCSK9 inhibitor Enlicitide has successfully completed Phase III clinical trials, potentially offering new options for cardiovascular disease patients [4] - The animal health business is expected to generate $6.4 billion in sales by 2025, reflecting an 8% year-over-year growth, while the diabetes drug sitagliptin is projected to generate $2.544 billion in revenue [4] Company Status - Merck's 2025 financial report anticipates 2026 sales between $65.5 billion and $67 billion, with adjusted EPS ranging from $5 to $5.15, which is below market expectations [5] - The company faces challenges including a decline in sales of the HPV vaccine Gardasil (projected at $5.2 billion for 2025, down 39% year-over-year), a slow recovery in the Chinese market, and a 12% decrease in R&D investment [5] Institutional Views - In January 2026, Wolfe Research upgraded Merck's rating to "Outperform" with a target price of $135, citing the company's position in a catalyst-rich phase through acquisitions and product innovation [6] - As of February 2, 2026, Merck's stock was priced at $113.37, reflecting a 14.72% increase over the past 52 weeks [6]